ClinicalTrials.gg
TerminatedNCT03953456Updated Aug 31, 2020

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

A Phase 2 interventional study of elafibranor 120mg and Placebo in Non-Alcoholic Fatty Liver, sponsored by Genfit. Terminated at 1 site in Netherlands. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Why this study was terminated
Continuation of the trial cannot serve a scientific purpose

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands — 10 open to participants now, 13 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · Netherlands.

Enrollment
27th of 32
17 · median 67
Started
2019
with 5 others
Phase 2
10 of 42
1 open now
Registered
19th of 42
by date
Lead sponsor
3 of 42
Genfit

Among the 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands, this one is the 27th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2019, is one of 10 in phase 2, and was the 19th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

10 of the 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands, or all of them as a file.
02

Study summary

This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks of treatment with a 4-week wash-out period. This study will achieve mechanistic information about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver

03

Conditions studied

  • Non-Alcoholic Fatty Liver

Keywords

  • Hepatic lipid composition
  • Elafibranor
  • Hepatic Glucose Production
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged from 40-75 years inclusive at first Screening Visit. (Post-menopausal defined as: subject should be surgically sterilized at least 6 months or no spontaneous menses for at least 1 year prior to screening)
  • Must provide signed written and agrees to comply with the study protocol.
  • Liver fat percentage ≥ 5 percent (as measured with Magnetic Resonance Spectroscopy)
  • 25.0 ≤ ≤ 38.0 kg/m\^2
  • Stable dietary habits and physical activity pattern (over 3 months prior to Screening Visit)
  • Subject agrees not to change dietary habits and physical activity pattern, to follow diet and lifestyle recommendations and not to consume or use illicit drugs during the study up to end of treatment.

Exclusion criteria

Exclusion Criteria:

Medical history:

  • Documented weight loss of more than 5 percent during the 6-month period prior to Screening Visit
  • for magnetic resonance imaging / spectroscopy
  • Known history of Type 1 and 2 diabetes
  • Known chronic heart failure (Grade I to IV of classification)
  • History of acute cardiac event within 6 months prior to Screening Visit such as: stroke, , or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures)
  • Uncontrolled hypertension despite optimal antihypertensive therapy
  • Other well documented causes of chronic liver disease according to standard diagnostic procedures.
  • Symptoms of clinical depression
  • Other concurrent medical (e.g., immunological, neoplastic, endocrine, hematological, gastrointestinal or neurological) or psychiatric condition, which, in the opinion of the Investigator, would place the subject at increased risk, preclude obtaining voluntary consent/assent or compliance with required study procedures, or would confound the objectives of study
  • Known to the investigation product or any of its formulation

Concomitant medications and lifestyle:

  • Fibrates are not permitted from 8 weeks before Screening up to end of treatment. Subjects taking statins or ezetimibe prior to Screening Visit 1 may participate if the dose has been stable for 3 months prior to Screening Visit 1 and no dose adjustments are anticipated
  • Currently taking drugs that can induce steatosis/steatohepatitis including, but not restricted to: (parenteral \& oral chronic administration only), amiodarone (Cordarone), tamoxifen (Nolvadex), and methotrexate (Rheumatrex, Trexall), which are not permitted 30 days prior to Screening and up to end of treatment
  • Subjects receiving thiazolidinediones (glitazones [pioglitazone, rosiglitazone])
  • Currently taking any medication that could interfere with study medication absorption, distribution, metabolism, or excretion or could lead to induction or inhibition of microsomal enzymes, e.g., indomethacin, which are not permitted from Randomization until end of treatment
  • Any medication use known to interfere with glucose homeostasis/metabolism
  • Smoking
  • Current or recent history (\<5years) of significant alcohol consumption. For men, significant consumption is typically defined as higher than 30 g pure alcohol per day. For women, it is typically defined as higher than 20 g pure alcohol per day
  • Subjects who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the month following the end of the study
  • Is participating in any other study and have received any other drug or device within 30 days prior to Screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments
  • Subjects who cannot be contacted in case of emergency

In addition to the above criteria, subject should not present any of the following biological exclusion criteria:

  • Positive anti- (HIV) antibody
  • Positive surface antigen
  • Positive Virus (HCV) antibody
  • (AST) and/or alanine aminotransferase (ALT) >5 x (ULN)
  • Conjugated > 1.50mg/dL due to altered hepatic function Note: Gilbert Disease subjects are allowed into the study
  • >1.40 due to altered hepatic function
  • count \<100,000/mm\^3 due to portal hypertension
  • Serum creatinine levels >1.53 mg/dL in males and >1.24 mg/dL in females
  • Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as subjects with markers of kidney damage or estimated (eGFR) of less than 60 ml/min/1.73 m\^2)
  • Unexplained serum creatine phosphokinase (CPK) >2 x ULN. In case of explained elevated CPK >2 x ULN, the measurement can be repeated prior to Randomization. In this case, retest should be performed within 1 to 2 weeks after initial test. A CPK retest >2 x ULN leads to exclusion
  • (HbA1C) > 6.4% and/or fasting plasma glucose (FGP) > 126 mg/dl
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    elafibranor 120mg followed by placebo

    Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks

    Drug: elafibranor 120mg · Drug: Placebo

  • Placebo comparator
    placebo followed by elafibranor 120mg

    Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks

    Drug: elafibranor 120mg · Drug: Placebo

Interventions

  • elafibranor 120mg is a coated tablet for oral administration, once daily

    Also known as: GFT505

  • DrugPlacebo

    Placebo is a coated tablet for oral administration, once daily

06

What researchers measure

Primary outcomes

  1. Change in relative amount of saturated fatty acids in the liver

    Relative amount of saturated fatty acids (SFA) in the liver measured by Magnetic Resonance Spectroscopy (1H-MRS) at the end of 6 weeks treatment period

    Time frame: After 6 weeks

Secondary outcomes

  1. Change in hepatic insulin sensitivity

    Hepatic insulin sensitivity measured by Hepatic Glucose Production (HGP) at the end of 6 weeks treatment period

    Time frame: After 6 weeks

  2. Glucose homeostasis markers

    Fasting glycemia

    Time frame: After 6 weeks

  3. Glucose homeostasis markers

    HbA1c

    Time frame: After 6 weeks

  4. Glucose homeostasis markers

    Fasting insulinemia

    Time frame: After 6 weeks

  5. Glucose homeostasis markers

    C-peptide

    Time frame: After 6 weeks

  6. Glucose homeostasis markers

    Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index

    Time frame: After 6 weeks

  7. Glucose homeostasis markers

    Fructosamine

    Time frame: After 6 weeks

  8. Lipid metabolism markers

    Triglycerides (TG)

    Time frame: After 6 weeks

  9. Lipid metabolism markers

    Total cholesterol (TC)

    Time frame: After 6 weeks

  10. Lipid metabolism markers

    High density lipoprotein-cholesterol (HDL-C)

    Time frame: After 6 weeks

  11. Lipid metabolism markers

    Low density lipoprotein-cholesterol (LDL-C)

    Time frame: After 6 weeks

  12. Lipid metabolism markers

    Non-HDL-C

    Time frame: After 6 weeks

  13. Lipid metabolism markers

    Free fatty acid (FFA)

    Time frame: After 6 weeks

  14. Inflammatory markers

    High sensitivity C-reactive protein (hs-CRP)

    Time frame: After 6 weeks

  15. Inflammatory markers

    Fibrinogen

    Time frame: After 6 weeks

  16. Inflammatory markers

    Haptoglobin

    Time frame: After 6 weeks

  17. Liver function

    Alanine aminotransferase (ALT)

    Time frame: After 6 weeks

  18. Liver function

    Aspartate aminotransferase (AST)

    Time frame: After 6 weeks

  19. Liver function

    Gamma glutamyl transferase (GGT)

    Time frame: After 6 weeks

  20. Liver function

    Alkaline phosphatase (ALP)

    Time frame: After 6 weeks

  21. Liver function

    Total and conjugated bilirubin

    Time frame: After 6 weeks

  22. Renal function

    Creatinine

    Time frame: After 6 weeks

  23. Renal function

    Estimated glomerular filtration rate (using Modification of Diet in Renal Disease (MDRD) formula)

    Time frame: After 6 weeks

  24. Renal function

    Blood urea nitrogen

    Time frame: After 6 weeks

  25. Renal function

    Albumin

    Time frame: After 6 weeks

  26. Renal function

    Uric acid

    Time frame: After 6 weeks

  27. Renal function

    Total proteins

    Time frame: After 6 weeks

  28. Body weight

    Time frame: After 6 weeks

  29. Body Mass Index

    Time frame: After 6 weeks

  30. Waist circumference

    Time frame: After 6 weeks

  31. Incidence and severity of treatment emergent adverse events (TEAEs) and their relationship to study drug

    Time frame: After 6 weeks

  32. Incidence of clinically meaningful changes from baseline in safety laboratory parameters, and vital signs

    Time frame: After 6 weeks

07

Study locations

1 site
  • NUTRIM School of Nutrition and Translational Research in Metabolism
    Maastricht, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Mar 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 16, 2019
StartActual
Aug 16, 2019
Primary completionActual
Mar 11, 2020
CompletionActual
Jul 14, 2020
Last update
Aug 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03953456
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
May 16, 2019
Start date
Aug 16, 2019
Primary completion
Mar 11, 2020
Completion
Jul 14, 2020
Last update
Aug 31, 2020

Study contacts

Pascal Birman, MD
study director · Genfit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion